Added value of this study
CVID, CLL, XLA, SARS-CoV-2 infections
CLL, SARS-COV-2 INFECTION, CVID
The present study, involving 356 study subjects from the COVAXID cohort, followed five major immunocompromised patient groups and respective subgroups as well as healthy controls over one year in a real-world setting. The study subjects were followed since the very first vaccine dose with longitudinal blood samplings and documentation of booster mRNA vaccine doses as well as SARS-CoV-2 infections following an initial two-dose regimen of BNT162b2 mRNA vaccination. In terms of long-term antibody responses to SARS-CoV-2 mRNA vaccination, our data grossly identifies three classes of immunocompromised patients broadly defined by their serological response patterns; 1) strong responders, e.g., patients having undergone HSCT and people living with HIV (PLWH), 2) weak responders, e.g., patients having undergone SOT and treated with MMF, patients with CVID, and patients with CLL treated with ibrutinib, and 3) non-responders, e.g., patients with XLA. The “strong responders” showed responses equivalent to healthy controls over time. Taken together, the study identifies particularly vulnerable patient groups in terms of immunogenicity-related responses among a large group of patients with primary and secondary immunodeficiencies.